Secreted phospholipase A2 in Multiple Sclerosis and EAE
Author Information
Author(s): Cunningham Timothy J, Yao Lihua, Oetinger Michelle, Cort Laura, Blankenhorn Elizabeth P, Greenstein Jeffrey I
Primary Institution: Drexel University College of Medicine
Hypothesis
The study tests the involvement of systemic secreted phospholipase A2 enzymes in experimental autoimmune encephalomyelitis and whether enzyme activity is elevated in MS patients.
Conclusion
The results suggest that sPLA2 enzymes are therapeutic targets for MS.
Supporting Evidence
- sPLA2 levels increased significantly in the urine of MS patients compared to healthy controls.
- CHEC-9 treatment reduced EAE symptoms in rats.
- The study used a non-invasive urinary assay to monitor enzyme levels.
Takeaway
This study found that a specific enzyme related to inflammation is higher in people with multiple sclerosis, and blocking this enzyme helped reduce symptoms in rats.
Methodology
A urinary assay was developed to monitor sPLA2 levels in rats and MS patients, with treatment involving a peptide inhibitor.
Potential Biases
Potential bias in scoring due to subjective assessments by investigators.
Limitations
The study may not fully account for variability in enzyme levels due to external factors.
Participant Demographics
44 MS patients (12 with active disease, 32 stable) and 14 healthy controls.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website